Cellectis S.A. (NASDAQ:CLLS)’s share price hit a new 52-week high during trading on Monday . The company traded as high as $32.18 and last traded at $32.18, with a volume of 608,287 shares traded. The stock had previously closed at $28.76.

A number of equities analysts recently commented on CLLS shares. BidaskClub upgraded shares of Cellectis from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 23rd. Jefferies Group LLC set a $47.00 target price on shares of Cellectis and gave the stock a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research upgraded shares of Cellectis from a “hold” rating to a “buy” rating and set a $32.00 target price for the company in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. set a $40.00 target price on shares of Cellectis and gave the stock a “buy” rating in a research note on Wednesday, May 10th. Finally, SunTrust Banks, Inc. downgraded shares of Cellectis from a “buy” rating to a “hold” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Cellectis currently has an average rating of “Buy” and a consensus price target of $41.50.

The company’s market capitalization is $920.22 million. The stock’s 50-day moving average is $24.96 and its 200-day moving average is $24.09.

Institutional investors have recently added to or reduced their stakes in the stock. ARK Investment Management LLC increased its position in shares of Cellectis by 79.1% in the 2nd quarter. ARK Investment Management LLC now owns 4,038 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 1,784 shares during the last quarter. Eqis Capital Management Inc. increased its position in shares of Cellectis by 27.2% in the 2nd quarter. Eqis Capital Management Inc. now owns 10,687 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 2,287 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Cellectis by 132.1% in the 2nd quarter. Wells Fargo & Company MN now owns 9,550 shares of the biotechnology company’s stock worth $247,000 after purchasing an additional 5,435 shares during the last quarter. Vident Investment Advisory LLC increased its position in shares of Cellectis by 20.0% in the 1st quarter. Vident Investment Advisory LLC now owns 50,994 shares of the biotechnology company’s stock worth $1,224,000 after purchasing an additional 8,496 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of Cellectis in the 1st quarter worth about $214,000. 14.85% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Cellectis S.A. (CLLS) Hits New 52-Week High at $32.18” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/06/cellectis-s-a-clls-hits-new-52-week-high-at-32-18.html.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.